Table 3.
Correlations between FUCA1 expression and clinicopathological parameters of PCa patients.
| Characteristic | Low expression of FUCA1 n (%) | High expression of FUCA1 n (%) | p-Value |
|---|---|---|---|
| Patients | 249 (40.9%) | 250 (50.1%) | |
| Age | 0.006*** | ||
| ≤60 | 96 (19.2%) | 128 (25.7%) | |
| >60 | 153 (30.7%) | 122 (24.4%) | |
| PSA (ng/ml) | 0.092* | ||
| <4 | 199 (45%) | 216 (48.9%) | |
| ≥4 | 18 (4.1%) | 9 (2%) | |
| Pathological grade group | <0.001* | ||
| Low-grade group (Gleason score < 8) |
110 (22%) | 183 (36.7%) | |
| High-grade group (Gleason score ≥ 8) |
139 (31%) | 67 (13.4%) | |
| T stage | <0.001* | ||
| T2 | 68 (13.8%) | 121 (24.6%) | |
| T3 and T4 | 178 (36.2%) | 125 (25.4%) | |
| N stage | 0.004* | ||
| N0 | 168 (39.4%) | 179 (42%) | |
| N1 | 53 (12.4%) | 26 (6.1%) | |
| M stage | 0.621** | ||
| M0 | 225 (49.1%) | 230 (50.2%) | |
| M1 | 2 (0.4%) | 1 (0.2%) | |
| Primary therapy outcome | <0.001* | ||
| PR and CR | 171 (39.1%) | 210 (48%) | |
| PD and SD | 43 (9.9%) | 14 (3.2%) | |
| Residual tumor | <0.001** | ||
| R0 | 140 (29.9%) | 175 (37.4%) | |
| R1 and R2 | 92 (19.6%) | 61 (13.1%) | |
| OS event, n (%) | 0.063** | ||
| Alive | 241 (48.3%) | 248 (49.7%) | |
| Dead | 8 (1.6%) | 2 (0.4%) | |
| DSS event, n (%) | 0.684** | ||
| Alive | 244 (49.1%) | 248 (49.9%) | |
| Dead | 3 (0.6%) | 2 (0.4%) | |
| PFI event, n (%) | <0.001* | ||
| Alive | 184 (36.9%) | 221 (44.3%) | |
| Dead | 65 (13%) | 29 (5.8%) |
p < 0.05 is considered as statistically significant.
PCa, prostate cancer; BPH, benign prostate hyperplasia; OS, overall survival; DSS, disease-specific survival; PFI, progression-free interval; PR, partial response; CR, complete response; PD, progressive disease; SD, stable disease.
*p: chi-square test.
**p: Fisher’s test.
***p: Wilcoxon rank-sum test.